Multiplexed fluorescence in situ hybridization-based detection of circulating tumor cells: A novel liquid-based technology to facilitate accurate and early identification of non-small cell lung cancer patients

Multiplexed fluorescence in situ hybridization-based circulating tumor cell (CTC) technology detects cytogenetic abnormalities in patients who are at risk for non-small cell lung cancer with high accuracy. Combined with low-dose computed tomography, this CTC technology can efficiently rule out malignancy in at-risk patients with benign pulmonary nodules.